×
About 12,367 results

ALLMedicine™ Bone Metastases Center

Research & Reviews  5,781 results

Quality of life and pain in patients with metastatic bone disease from solid tumors tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893880
BMC Cancer; Ribi K, Thürlimann B et. al.

Feb 20th, 2021 - Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. Th...

Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast canc...
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.

Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...

Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteocla...
https://doi.org/10.2174/1874467214666210211162118
Current Molecular Pharmacology; Vashum Y, Kottaiswamy A et. al.

Feb 12th, 2021 - Breast cancer (BC) produces bone resorptive cytokines and growth factors which accelerate the development of osteoclasts (OCs), leading to osteolytic bone metastases. In the Long-term Odanacatib Fracture Trial (LOFT), the skeletal-metastasized bre...

Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
https://doi.org/10.1097/RLU.0000000000003522
Clinical Nuclear Medicine; Xu G, Lu Y

Feb 12th, 2021 - Patient was a 73-year-old woman with metastatic renal cell carcinoma. Bone scan showed multifocal bone metastases. The patient received cabozantinib treatment for more than 1 year. On the follow-up bone scan, the previously biopsy-proven left pelv...

see more →

Guidelines  21 results

Physician Practice Variability in the Use of Extended-Fraction Radiation Therapy for Bone Metastases: Are We Choosing Wisely?
https://ascopubs.org/doi/abs/10.1200/JOP.19.00633?journalCode=op
JCO Oncology Practice; Gupta A

Apr 12th, 2020 - Routine use of extended-fraction (> 10 fractions) radiation therapy (RT) for palliation of bone metastases is recognized as a low-value intervention by the American Society for Radiation Oncology. We examined contemporary practice patterns of, and...

Palliative radiation therapy for bone metastases
https://www.practicalradonc.org/article/S1879-8500(16)30122-9/pdf?code=prro-site
Stephen Lutz

Jan 31st, 2017 - This guideline update addresses the eight questions from the original bone metastases guideline published in 2011 based on new literature. It first discusses effective fractionation schemes to treat pain and/or prevent morbidity from peripheral bo.

SEOM Clinical Guideline for bone metastases from solid tumours (2016).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138247
Clinical & Translational Oncology : Official Publication ... Grávalos C, Rodríguez C et. al.

Nov 29th, 2016 - Bone metastases are common in many advanced solid tumours, being breast, prostate, thyroid, lung, and renal cancer the most prevalent. Bone metastases can produce skeletal-related events (SREs), defined as pathological fracture, spinal cord compre...

Bone health in cancer patients: ESMO Clinical Practice Guidelines.
https://doi.org/10.1093/annonc/mdu103
Annals of Oncology : Official Journal of the European Soc... Coleman R, Body JJ et. al.

May 1st, 2014 - There are three distinct areas of cancer management that make bone health in cancer patients of increasing clinical importance. First, bone metastases are common in many solid tumours, notably those arising from the breast, prostate and lung, as w...

Prostate cancer, version 1.2014.
https://doi.org/10.6004/jnccn.2013.0174
Journal of the National Comprehensive Cancer Network : JN... Mohler JL, Kantoff PW et. al.

Dec 17th, 2013 - The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceut...

see more →

Drugs  81 results see all →

Clinicaltrials.gov  6,171 results

Quality of life and pain in patients with metastatic bone disease from solid tumors tre...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893880
BMC Cancer; Ribi K, Thürlimann B et. al.

Feb 20th, 2021 - Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. Th...

Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast canc...
https://doi.org/10.1097/CAD.0000000000001051
Anti-cancer Drugs; Ponnapakkam T, Anbalagan M et. al.

Feb 17th, 2021 - Patients with advanced breast cancer often develop bone metastases. Treatment is limited to palliative care. Parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) antagonists for bone metastases failed clinically due to short half-...

Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteocla...
https://doi.org/10.2174/1874467214666210211162118
Current Molecular Pharmacology; Vashum Y, Kottaiswamy A et. al.

Feb 12th, 2021 - Breast cancer (BC) produces bone resorptive cytokines and growth factors which accelerate the development of osteoclasts (OCs), leading to osteolytic bone metastases. In the Long-term Odanacatib Fracture Trial (LOFT), the skeletal-metastasized bre...

Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
https://doi.org/10.1097/RLU.0000000000003522
Clinical Nuclear Medicine; Xu G, Lu Y

Feb 12th, 2021 - Patient was a 73-year-old woman with metastatic renal cell carcinoma. Bone scan showed multifocal bone metastases. The patient received cabozantinib treatment for more than 1 year. On the follow-up bone scan, the previously biopsy-proven left pelv...

see more →

News  313 results

Jaw Necrosis Risk in Cancer Patients on Zoledronic Acid Varies With Dosing, Oral Health
https://www.medscape.com/viewarticle/943201

Dec 27th, 2020 - NEW YORK (Reuters Health) - In patients treated with zoledronic acid for bone metastases, the risk of osteonecrosis of the jaw (ONJ) was associated with cancer type, oral health and dosing frequency, researchers found in a recent study. Overall, a...

Gene Signature Predicts Risk of Metastasis in Localised Prostate Cancer
https://www.medscape.com/viewarticle/941105

Nov 16th, 2020 - Researchers have identified a genetic signature in localised prostate cancer that can predict whether the cancer is likely to metastasise early in the course of the disease and whether it will respond to anti-androgen therapy. The new gene signatu...

Ipilimumab Prolongs Overall Survival in Metastatic Castration-Resistant Prostate Cancer
https://www.medscape.com/viewarticle/937000

Sep 8th, 2020 - NEW YORK (Reuters Health) - Treatment with ipilimumab following radiotherapy to bone metastases in men with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel is associated with improved overall survival, acc...

Ipilimumab Prolongs Overall Survival in Metastatic Castration-Resistant Prostate Cancer
https://www.staging.medscape.com/viewarticle/937000

Sep 8th, 2020 - NEW YORK (Reuters Health) - Treatment with ipilimumab following radiotherapy to bone metastases in men with metastatic castration-resistant prostate cancer (mCRPC) who previously received docetaxel is associated with improved overall survival, acc...

ESMO Guidelines on the Management of Bone Health in Patients With Cancer
https://www.medscape.com/viewarticle/936217

Aug 23rd, 2020 - The European Society for Medical Oncology (ESMO) has published new guidelines on the management of bone health in patients with cancer. Key recommendations include the following: CT and MRI are modalities of choice for routine response assessment ...

see more →